US Stock MarketDetailed Quotes

CLRB Cellectar BioSciences

Watchlist

1.9900
-0.0400-1.97%

Trading Aug 16 10:11 ET

71.34MMarket Cap-644P/E (TTM)

Cellectar BioSciences Stock Forum

Trytosaveabit

Jul 23 11:50

Hehehe!

$Cellectar BioSciences (CLRB.US)$ Look at that! Good PR price falls! But now its up almost 20% from the low it dropped to

Trytosaveabit

Jul 23 06:24

Just thinking outloud

$Cellectar BioSciences (CLRB.US)$ Hoping that was a great dip for buying? Hehehe. NFA

Trytosaveabit

Jul 23 05:56

Update

$Cellectar BioSciences (CLRB.US)$ Cellectar Biosciences’ Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom’s Macroglobulinemia Pivotal Study With 78% of Major Response Patients Remaining Progression Free at 18 Months

TrendTrader

Jul 22 11:00

3 🎯 hit!

$Cellectar BioSciences (CLRB.US)$

TrendTrader

Jul 22 10:35

Over 3 looking for 3.4

$Cellectar BioSciences (CLRB.US)$

Jaguar8

May 29 06:19

NEWS

$Cellectar BioSciences (CLRB.US)$
Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis Fungoides
Cellectar Biosciences (NASDAQ: CLRB) has formed a strategic partnership with City of Hope Cancer Center to evaluate the efficacy of its lead drug, iopofosine I 131, in treating mycosis fungoides (MF), a rare form of non-Hodgkin's lymphoma (NHL). This collaboration aims to initiate trials with around 10 patients by late 2024 or early 202...

Meltyy

May 22 02:52

Biotech Stock Catalyst Watchlist 👀

🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...

Trytosaveabit

Mar 4 05:45

Update

$Cellectar BioSciences (CLRB.US)$ Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer
4 MINUTES AGO, 6:40 AM EST
VIA GLOBENEWSWIRE